Generated by AI
Vericel Corporation is a commercial-stage biopharmaceutical company focused on advanced cell therapies and specialty biologics for sports medicine and severe burn care. Vericel develops, manufactures, and markets products that support the repair of damaged tissue and the restoration of function in patients with serious injuries. Its commercial portfolio includes MACI, a cell therapy used in knee cartilage repair; Epicel, a skin replacement product for severe burns; and NexoBrid, an enzymatic biologic used for eschar removal in burn care. The company serves hospitals, surgeons, and specialized care teams across the United States, with its products positioned within regenerative medicine and acute wound care. Vericel’s business centers on translating cell-based science into practical treatments for complex orthopedic and burn-related conditions.
Website64 Sidney Street
Cambridge, MA, 02139
United States
The latest articles about VCEL.
Summary of May 7's posts. Generated by AI.
Summary of Mar 19's posts. Generated by AI.
Summary of Jan 15's posts. Generated by AI.
Investors talking about VCEL also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.